ANALYSIS: Drug Discount Laws to Surge as Courts Back State Power

Recent court rulings that allow states to regulate drugmaker discount policies will pave the way for a surge of new state laws across the country in 2025. Big pharma companies will have to grapple with changing their practices under a federal discount program that they say is rampant with fraud and abuse.

At least five federal courts now are letting states bar drug manufacturers from refusing to supply discounted drugs to pharmacies that contract with eligible entities under the longstanding yet controversial federal 340B Drug Pricing Program. The cases are spotlighting a debate over federal versus state power within ...